Pfizer Inc. on April 29 said a large trial found that the company’s COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone infected with the virus.
Humira could generate more than $20 billion in sales for AbbVie during 2021 while Merck’s Keytruda is on track to become only the second prescription medicine ever to exceed $16 billion in annual sales.
The U.S. Food and Drug Administration approved Amgen Inc.’s biosimilar copy of Johnson & Johnson’s blockbuster rheumatoid arthritis (RA) drug Remicade.
A federal judge tossed out whistleblower lawsuits alleging that pharmaceutical giants Eli Lilly and Bayer used nurses to illegally boost sales of various prescription drugs in a kickback scheme.
Roche’s Tecentriq won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines.
Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.